2024
Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials
Conforti A, Carbone L, Di Girolamo R, Iorio G, Guida M, Campitiello M, Ubaldi F, Rienzi L, Vaiarelli A, Cimadomo D, Ronsini C, Longobardi S, D'Hooghe T, Esteves S, Alviggi C. Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials. Fertility And Sterility 2024 PMID: 39332623, DOI: 10.1016/j.fertnstert.2024.09.038.Peer-Reviewed Original ResearchDiminished ovarian reserveLive birth rateOvarian reserveRandomized controlled trialsClinical management of womenHigher live birth ratesAssociated with higher live birth ratesMeta-analysis of randomized controlled trialsControlled trialsInvestigate adjuvant treatmentsManagement of womenLow-dose gonadotropinsLuteal phase stimulationBirth ratePOSEIDON criteriaCorifollitropin alfaAdjuvant treatmentGonadotropin regimensGnRH antagonistClomiphene citrateLuteinizing hormoneTherapeutic managementTestosterone supplementationClinical managementRandomized trials
2023
Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35–40 years
Bielfeld A, Schwarze J, Verpillat P, Lispi M, Fischer R, Hayward B, Chuderland D, D'Hooghe T, Krussel J. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35–40 years. Reproductive BioMedicine Online 2023, 48: 103725. PMID: 38593745, DOI: 10.1016/j.rbmo.2023.103725.Peer-Reviewed Original ResearchAdvanced maternal ageWomen of advanced maternal ageR-hLHR-hFSHRecombinant human FSHLive birthsClinical pregnancyOvarian stimulationHuman FSHPost hoc analysis of womenRecombinant human LHLive birth rateNormal ovarian reserveNon-interventional studyAssisted reproductive technologyAnalysis of womenPost hoc analysisOvarian reserveMaternal ageEffects of treatmentHuman LHAlone groupPatient groupClinical trialsART treatmentP-238 Non-interventional study comparing the effectiveness and safety of r-hFSH:r-hLH versus r-hFSH in women aged 35-42 years with normal ovarian reserve undergoing GnRH antagonist ART treatment
Arvis P, Lehert P, Chuderland D, Schwarze J, Helwig C, Bidet M, Guivarc'h Leveque A, Lispi M, D'Hooghe T. P-238 Non-interventional study comparing the effectiveness and safety of r-hFSH:r-hLH versus r-hFSH in women aged 35-42 years with normal ovarian reserve undergoing GnRH antagonist ART treatment. Human Reproduction 2023, 38 DOI: 10.1093/humrep/dead093.596.Peer-Reviewed Original ResearchNormal ovarian reserveR-hLHR-hFSHLive birth rateOvarian stimulationOvarian reserveNon-interventional studyART treatmentFrench centersLive birthsPregnancy rateOS cyclesClinical pregnancy rateAdvanced maternal ageOngoing pregnancy rateOvarian reserve biomarkersLow ovarian reserveAnalysis of clinical dataSubgroup of patientsFollow-up periodPregnancy failure rateBirth rateSecondary analysis of clinical dataClinical pregnancyAMH levels